Biotech entity
Roundup is most often covered alongside Bayer, which appears in 1 of these 2 stories. The 133-day window averages about 0.1 stories each week. Source depth averages 2 original sources per story, versus 3.5 across the same-window beat baseline. The 7.5 average consequence score is above the beat benchmark of 6.1 in the same window.
Last mentioned: Jun 30, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Roundup is most often covered alongside Bayer, which appears in 1 of these 2 stories. The 133-day window averages about 0.1 stories each week. Source depth averages 2 original sources per story, versus 3.5 across the same-window beat baseline. The 7.5 average consequence score is above the beat benchmark of 6.1 in the same window. fda-approval accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Roundup appears in 2 tracked Biotech stories published from February 18, 2026 through June 30, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 516 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Roundup. Shared-story counts are live from our verified record — not editorial picks.
End of Certainty Period
The 21-year structured resolution period is slated to conclude.
$7.25B Settlement Announced
Bayer agrees to a new $7.25 billion deal with a 21-year certainty plan.
Initial $10B Settlement
Bayer announces a massive settlement to resolve current claims, but future liability remains.
Monsanto Acquisition
Bayer completes $63 billion acquisition of Monsanto, inheriting Roundup litigation.
The U.S. Supreme Court ruled that FIFRA preempts state failure-to-warn claims against Bayer's Roundup, eliminating a massive source of litigation uncertainty. The 7-2 decision validates EPA's safety assessment of glyphosate and sharply reduces Bayer's outstanding tort exposure, potentially freeing up billions in capital for the biotech giant.
Source: National Law Review · National Law Review
Bayer has reached a $7.25 billion settlement agreement to resolve long-standing litigation surrounding its Roundup herbicide. The deal includes a 21-year framework designed to provide legal and financial certainty for the company following years of costly courtroom battles.
Roundup is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
